Hepatitis B vaccine - Emergent BioSolutions

Drug Profile

Hepatitis B vaccine - Emergent BioSolutions

Alternative Names: HBV vaccine - Emergent BioSolutions

Latest Information Update: 23 Jul 2015

Price : $50

At a glance

  • Originator Emergent BioSolutions
  • Class Hepatitis B vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hepatitis B

Most Recent Events

  • 26 Mar 2007 Phase II development is ongoing
  • 27 Jun 2005 Microscience has been acquired by Emergent BioSolutions
  • 08 Nov 2004 Microscience has completed a phase I trial in Hepatitis B treatment in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top